GFM
KRYS icon

GF Fund Management’s Krystal Biotech KRYS Stock Holding History

GF Fund Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168K Buy
651
+82
+14% +$21.8K ﹤0.01% 299
2025
Q4 		$140K Sell
569
-54
-9% -$11.4K ﹤0.01% 319
2025
Q3 		$110K Sell
623
-113
-15% -$16.9K ﹤0.01% 329
2025
Q2 		$101K Hold
736
– – ﹤0.01% 365
2025
Q1 		$133K Buy
736
+132
+22% +$22.2K ﹤0.01% 347
2024
Q4 		$94.6K Buy
+604
New +$107K ﹤0.01% 335

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GF Fund Management's KRYS Position: Q1 2026 in Review

GF Fund Management increased its Krystal Biotech (KRYS) stake by 14% in Q1 2026, buying an estimated $21.8K and bringing the position to 651 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #299.

GF Fund Management first reported a position in KRYS in Q4 2024 and has held it in 6 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • GF Fund Management held 651 shares of Krystal Biotech worth $168K as of Q1 2026.
  • GF Fund Management bought 82 Krystal Biotech shares in Q1 2026, an estimated $21.8K.
  • Krystal Biotech made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #299 holding.
  • GF Fund Management first reported a position in Krystal Biotech in Q4 2024 and has held it in 6 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.